CVKD – cadrenal therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibito
Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System [Yahoo! Finance]
Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On [Yahoo! Finance]
Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026
Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT) [Yahoo! Finance]
Form 424B3 Cadrenal Therapeutics,
Form EFFECT Cadrenal Therapeutics,
Form D Cadrenal Therapeutics,
Form 4 Cadrenal Therapeutics, For: Dec 29 Filed by: Szot Matthew K
Form 144 Cadrenal Therapeutics, Filed by: Szot Matthew K
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.